arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Wave Life Sciences Ltd.

WVE
$3.21 ▼ -0.40 (-10.94%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
52 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Wave Life Sciences Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $655.6M
Dividend Yield —
Revenue Growth 72.9% ↗
Op. Margin None
ROIC -16.4% →
FCF / Share $-0.29 ↘
Trailing P/E —
Price / Book 1.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.16M
↑ +72.9% —
Net Income Profit after all expenses
$-26.09M
↑ +44.4% —
Operating Margin Operating profit as % of sales
-81.8%
↑ +75.0% —
FCF / Share Free cash flow per share
$-0.29
↓ -10.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↑
19
Cash Quality ↑
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters